Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Disease duration influences gene expression in neuromelanin-positive cells from Parkinson’s disease patients

ABSTRACT: Disease duration influences gene expression in neuromelanin-positive cells from Parkinson’s disease patients

PROVIDER: PRJNA757020 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15570000.fastq.gz	Fastqsanger.gz
	SRR15570100.fastq.gz	Fastqsanger.gz
	SRR15570001.fastq.gz	Fastqsanger.gz
	SRR15570101.fastq.gz	Fastqsanger.gz
	SRR15570002.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 270

Similar Datasets

Disease duration influences gene expression in neuromelanin-positive cells from Parkinson’s disease patients

Project description:We used RNAseq to analyze genome-wide gene expression in mDA neurons isolated by LCM from postmortem cases of PD. Patients samples are derived both early after diagnosis and after prolonged disease duration. Cases of ILBD and age-matched controls were also included in the analysis.

2021-11-08 | GSE182622 | GEO

NINDS Parkinson’s Disease

Project description:NINDS Parkinson’s Disease

| PRJNA330889 | ENA

Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson’s disease

Project description:Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson’s disease

| PRJNA804908 | ENA

Enriched environmental conditions modify the gut microbiome composition and fecal markers of inflammation in Parkinson’s disease

Project description:We used a transgenic mouse model overexpressing the complete human SNCA genes modeling familial and sporadic forms of Parkinson’s disease to study whether environmental conditions such as standard versus enriched environment changes the gut microbiome and influences disease progression.

2019-10-01 | GSE137213 | GEO

The Gut Microbiome in Parkinson’s Disease

Project description:The Gut Microbiome in Parkinson’s Disease

| PRJNA671238 | ENA

The Gut Microbiome in Parkinson’s Disease

Project description:The Gut Microbiome in Parkinson’s Disease

| PRJNA671239 | ENA

Mitochondrial DNA allelic substitutions in Parkinson’s disease

Project description:Mitochondrial DNA allelic substitutions in Parkinson’s disease

| PRJNA453701 | ENA

A splice isoform signature of Parkinson’s disease in peripheral blood

Project description:In these studies, we used splice variant-specific microarrays manufactured by the ExonHit company ( www.exonhit.com) on the Affymetrix platform. The goal was to identify splice isoforms whose expression is altered in whole blood of early-stage Parkinson’s disease patients compared to healthy and neurodegenerative disease controls. The study included 19 cases of Parkinson’s disease (PD) samples, 4 of multiple system atrophy (MSA), 4 progressive supranuclear palsy (PSP) and 10 healthy controls. Thirteen splice variants were confirmed in quantitative polymerase chain reactions and used to classify blinded samples from Parkinson’s disease patients and controls with 90% accuracy and 94% sensitivity.

2012-12-01 | GSE34287 | GEO

Hsa-miR-144-3p is down-regulated in serum from drug-naïve and advanced Parkinson’s disease patients.

Project description:Advanced age represents one of the major risk factors for Parkinson’s Disease. Recent studies posit a role for microRNAs in Parkinson’s Disease and it is well established that microRNAs are remodelled during ageing, but the relationship between the two processes have not been clarified yet. The aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson’s Disease within the ageing framework. We used Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson’s Disease (recently diagnosed, drug-naïve Parkinson’s Disease patients) and healthy ageing (centenarians) plus healthy controls age-matched with Parkinson’s Disease patients. Potential candidates, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson’s Disease patients together with healthy siblings of Parkinson’s Disease patients at higher genetic risk for Parkinson’s Disease. While we did not find evidences of microRNAs co-regulated in Parkinson’s Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early and advanced Parkinson’s Disease and in Parkinson’s Disease siblings. Interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson’s Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early and advanced Parkinson’s Disease, robustly confirmed across a variety of analytical and experimental analyses. These results are promising, and additional research is needed to unveil the functional details of its relevance and involvement in Parkinson’s Disease.

2022-02-02 | GSE180193 | GEO